GlaxoSmithKline (LON:GSK) paid nearly $10 billion in inflation-adjusted financial penalties between January 2003 and December 2016, the highest tally for any drug company, according to research published in JAMA. That sum was more than any other in a sampling of 26 companies paying fines inside the U.S. Pfizer (NYSE: PFE) was next in line with…